Cargando…

Optimizing the management of transthyretin familial amyloid polyneuropathy in Europe: early diagnosis and effective care

Detalles Bibliográficos
Autor principal:	Adams, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Supplement Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739315/ https://www.ncbi.nlm.nih.gov/pubmed/26794616 http://dx.doi.org/10.1097/WCO.0000000000000294

Ejemplares similares

First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
por: Adams, David, et al.
Publicado: (2016)

The rehabilitation in the management of Transthyretin Familial Amyloid Polyneuropathy
por: Morier, Agnès, et al.
Publicado: (2015)

Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP
por: Parman, Yesim, et al.
Publicado: (2016)

Transthyretin familial amyloid polyneuropathy (TTR‐FAP): Parameters for early diagnosis
por: Escolano‐Lozano, Fabiola, et al.
Publicado: (2017)

Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
por: Rousseau, Antoine, et al.
Publicado: (2015)

Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal
por: Inês, Mónica, et al.
Publicado: (2015)

Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H.‐J., et al.
Publicado: (2016)

Estimating the global prevalence of transthyretin familial amyloid polyneuropathy
por: Schmidt, Hartmut H., et al.
Publicado: (2018)

Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France
por: Mariani, Louise‐Laure, et al.
Publicado: (2015)

“Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathy
por: Conceição, Isabel, et al.
Publicado: (2016)

Vasculopathy in transthyretin Val30Met familial amyloid polyneuropathy
por: Koike, Haruki, et al.
Publicado: (2015)

Ophtalmologic changes in transthyretin familial amyloid polyneuropathy (ATTR-FAP)
por: Ferreira, Natália
Publicado: (2015)

Psychopathological Dimensions in Portuguese Subjects with Transthyretin Familial Amyloid Polyneuropathy
por: Lopes, Alice, et al.
Publicado: (2017)

Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
por: Sekijima, Yoshiki, et al.
Publicado: (2018)

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2013)

Nerve Ultrasound Comparison Between Transthyretin Familial Amyloid Polyneuropathy and Chronic Inflammatory Demyelinating Polyneuropathy
por: Du, Kang, et al.
Publicado: (2021)

Transthyretin familial amyloid polyneuropathy impact on health-related quality of life
por: Inês, Mónica, et al.
Publicado: (2015)

Clinical and genetic features of transthyretin-related familial amyloid polyneuropathy in China
por: Liu, Lei, et al.
Publicado: (2020)

Correction to: Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
por: Sekijima, Yoshiki, et al.
Publicado: (2019)

Clinical, epidemiological, genetic, and electrophysiological characteristics of transthyretin familial amyloid polyneuropathies in Israel
por: Sadeh, Menachem, et al.
Publicado: (2015)

Inflammatory state exists in familial amyloid polyneuropathy that may be triggered by mutated transthyretin
por: Suenaga, Genki, et al.
Publicado: (2017)

Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer
por: Cotrina, Ellen Y., et al.
Publicado: (2020)

Transthyretin interacts with actin regulators in a Drosophila model of familial amyloid polyneuropathy
por: I. Oliveira da Silva, Marina, et al.
Publicado: (2020)

Vagus nerve ultrasound in transthyretin familial amyloid polyneuropathy: A pilot study
por: Du, Kang, et al.
Publicado: (2021)

Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy
por: Romero-Imbroda, Jesús, et al.
Publicado: (2017)

Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015)

Transthyretin familial amyloid polyneuropathy (TTR-FAP) in Mallorca: a comparison between late- and early-onset disease
por: Raya-Cruz, Manuel, et al.
Publicado: (2015)

Post Hoc Analysis of Nutritional Status in Patients with Transthyretin Familial Amyloid Polyneuropathy: Impact of Tafamidis
por: Suhr, Ole B., et al.
Publicado: (2014)

Early intervention with tafamidis provides long-term benefit in delaying neurological progression in patients with transthyretin familial amyloid polyneuropathy
por: Waddington-Cruz, Marcia, et al.
Publicado: (2015)

Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
por: González‐Duarte, Alejandra, et al.
Publicado: (2020)

Patterns of myelinated nerve fibers loss in transthyretin amyloid polyneuropathy and mimics
por: Du, Kang, et al.
Publicado: (2022)

Hereditary Transthyretin Amyloidosis with Polyneuropathy: Monitoring and Management
por: Vélez-Santamaría, Valentina, et al.
Publicado: (2022)

Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Llàtzer Hospital descriptive study
por: Reinés, Juan Buades, et al.
Publicado: (2014)

Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis
por: Zhao, Yinan, et al.
Publicado: (2019)

Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy
por: Warendorf, Janna K., et al.
Publicado: (2023)

Prevalence of hereditary transthyretin amyloid polyneuropathy in idiopathic progressive neuropathy in conurban areas
por: Thimm, Andreas, et al.
Publicado: (2019)

Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis
por: Obici, Laura, et al.
Publicado: (2016)

Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Mundayat, Rajiv, et al.
Publicado: (2018)

Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
por: Falcão de Campos, Catarina, et al.
Publicado: (2023)

Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uv52pmtvv8hv89tlgaevrn7scu